Yükleniyor... / Loading...
ß-Thalassemia Major With Autologous CD34+ Hematopoietic Progenitor Cells Transduced With TNS9.3.55 a Lentiviral Vector Encoding the Normal Human ß-Globin Gene
Bu çalışma, ß-talasemi majör (ß-thalassemia major) hastalarında bir gen terapisini incelemektedir; bu tedavide hastanın kendi CD34+ kan kök hücreleri, normal insan ß-globin genini taşıyan TNS9.3.55 adlı lentiviral vektör ile laboratuvarda değiştirilir. Çalışmaya, düzenli kan transfüzyonu alan, HLA-uyumlu kardeş vericisi bulunmayan 18 yaş ve üzeri hastalar alınmıştır. Çalışma Faz 1 aşamasında yürütülmüş; şu an katılımcı almamakta ancak devam etmektedir (active, not recruiting).
Yukarıdaki özet, resmî kaydın sade dile aktarılmış halidir. Orijinal İngilizce başlık referans için gösterilir.
Kriterler ClinicalTrials.gov kaydından orijinal İngilizce haliyle alınmıştır. Uygunluk kararını yalnızca deneyi yürüten ekip verebilir.
Inclusion Criteria:
* Subjects must be 18 years or older
* Subjects may be of either gender or of any ethnic background
* Subjects must have a confirmed diagnosis of ß-thalassemia major and have been enrolled in a hypertransfusion program with a confirmed annual transfusion of ≥100 mL/kg/yr but \< 200 mL/kg/yr, AND ≥ 8 transfusions of blood per year over a minimum of two years.
* Patients must NOT have an HLA-matched sibling
* Patients must be off hydroxyurea (HU) or erythropoietin (EPO) treatment for at least three months prior to entry onto the study
* Subjects must have a performance score of Karnofsky ≥70% at the time of entry into the study.
* Subjects must have liver iron value of \< 15 mg/g/dry weight Iron quantitation may be performed by imaging such as T2\*MRI or by biopsy
* Subjects must have no evidence of cirrhosis\*\* of the liver. Fibrosis of the liver can be tested by Fibroscan (47, 48, 49), or by liver biopsy. These should be performed within approximately a one year period prior to entry onto the study.
* Subjects with an evaluation of cardiac function indicating:
* normal function on MUGA scan (Multiple Gated Acquisition scan) or other methodology.
And
* Patients must have a left ventricular ejection fraction (LVEF) of ≥ 60% and/or T2\*MRI cardiac evaluation with T2\* ≥20 milliseconds
* Subjects with asymptomatic pulmonary function based on Lung Diffusion Testing DLCO Test DLCO ≥ 50% of predicted (corrected for hemoglobin)
* Subjects with a determination of renal function based on: serum creatinine \< than or = to 1.5 mg/dL or if serum creatinine is outside the normal range, then CrCl \> 60-ml/min/1.73 m2
* Subjects must have adequate hepatic function based on:
* \< 3 x ULN ALT and
* \< 2.0 total serum bilirubin (unless secondary to hemolysis)
* Patients must be available for follow-up evaluations at 30, 60, 180 days post BMT and yearly thereafter indefinitely.
* The possibility of unrelated donor stem cell transplantation will be discussed with patients, and a "preliminary" search for an unrelated donor may be done at the request of the patient. However, the finding of a potential HLA-matched unrelated donor will not exclude the patient from participating into this trial).
* As the inclusion criteria are more specific than the Lucarelli/Pesaro thalassemia pre-transplant classification (Class 1,2 or 3 according to presence or absence of fibrosis, adequate chelation and/or hepatomegaly), the criteria stated above will be used in lieu of the Lucarelli/Pesaro classification.
Exclusion Criteria:
* Active infections including Hepatitis B and Hepatitis C\*\*\*,
* Active infections including HTLV 1 and 2, and HIV 1 and 2
* Patients with treated HLTV or HIV
* Diabetes Mellitus
* Bone Marrow myelodysplasia and/or chromosomal abnormalities
* Female patient pregnant or breast feeding
* Patients with uncontrolled seizure disorders
* Patients with severe pulmonary hypertension Tricuspid Jet velocity \> 2.5 m/sec
* Family history of familial cancer syndromes (leukemia, breast, ovarian, colorectal, etc.)
\*\*\* Definition of active Hepatitis C include:
* Positive HCV RNA Viral load by quantitative PCR testing Or if Negative HCV RNA viral load BUT on antiviral treatment
* Liver biopsy with pathologic evidence of
* Necrosis and inflammation around the portal areas - piecemeal necrosis or interface hepatitis or necrosis of hepatocytes and focal inflammation in the liver parenchyma.
* Inflammatory cells in the portal areas ("portal inflammation").
* Fibrosis, with early stages being confined to the portal tracts, intermediate stages being expansion of the portal tracts and bridging between portal areas or to the central area, and late stages being frank cirrhosis characterized by architectural disruption of the liver with fibrosis and regeneration.